The mechanisms of action for eloralintide and incretins, like tirzepatide, are different.

• Eloralintide is a selective amylin receptor agonist.
• Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.1,2

Eli Lilly and Company is not developing eloralintide to replace tirzepatide for the treatment of obesity. Eloralintide could serve as an alternative to incretin therapies or a complementary option for patients that need higher levels of efficacy.3

Effectively treating obesity means providing patients with options that work for them, which may require investigating new mechanisms of action to offer alternatives to incretin therapies At Lilly, we are focusing on identifying multiple mechanisms, so people who are not fully served by current treatments have alternatives.2

Lilly plans to initiate phase 3 clinical studies of eloralintide as a monotherapy for the treatment of obesity and is evaluating its use as a complementary treatment to incretin therapy. Lilly is evaluating a number of possible incretin partners for eloralintide. Lilly is not ready to disclose dosing details for phase 3 trials at this time.2

For more information about Lilly’s clinical trials for eloralintide, please visit clinicaltrials.gov.

Lilly is not ready to disclose any plans on future on potential coformulations, but will continue to evaluate it use as a complementary treatment to incretin therapy.2